How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
| Autor: | Dhakshin S. Ramanathan, Hewa Artin, Sidney Zisook |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hallucinogen
Treatment response Depression business.industry Review Antidepressants Serotonergic 030227 psychiatry 03 medical and health sciences 0302 clinical medicine Serotonergic psychedelics Neuroplasticity Monoaminergic Psychedelics Hallucinogens Antidepressant Medicine Ketamine business Neuroscience 030217 neurology & neurosurgery Depression (differential diagnoses) Common mental disorder |
| Zdroj: | World Journal of Psychiatry |
| ISSN: | 2220-3206 |
| DOI: | 10.5498/wjp.v11.i6.201 |
| Popis: | Depression is a common mental disorder and one of the leading causes of disability around the world. Monoaminergic antidepressants often take weeks to months to work and are not effective for all patients. This has led to a search for a better understanding of the pathogenesis of depression as well as to the development of novel antidepressants. One such novel antidepressant is ketamine, which has demonstrated both clinically promising results and contributed to new explanatory models of depression, including the potential role of neuroplasticity in depression. Early clinical trials are now showing promising results of serotonergic psychedelics for depression; however, their mechanism of action remains poorly understood. This paper seeks to review the effect of depression, classic antidepressants, ketamine, and serotonergic psychedelics on markers of neuroplasticity at a cellular, molecular, electrophysiological, functional, structural, and psychological level to explore the potential role that neuroplasticity plays in the treatment response of serotonergic psychedelics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|